Information Provided By: 
Fly News Breaks for May 21, 2019
SNDX
May 21, 2019 | 08:30 EDT
Citi analyst Joel Beatty believes shares of Syndax Pharmaceuticals could trade up to $23 if the company's the Phase 3 trial of entinostat in metastatic breast cancer is positive. The analyst, who sees the stock trading down to $2 if the trial fails, assigns a 50% probability of success. He views the data, expected in fall 2019 or spring 2020 as the key catalyst for Syndax. Beatty keeps a Buy rating on the shares.
News For SNDX From the Last 2 Days
There are no results for your query SNDX
